GEN 2
Alternative Names: GEN2Latest Information Update: 13 Nov 2024
At a glance
- Originator GenVivo
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Thymidine kinase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Liver cancer
Most Recent Events
- 08 Nov 2024 Efficacy and adverse event data from a phase I/Ib trial in Solid tumours released by GenVivo
- 04 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06391918)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Liver-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Philippines (Intra-arterial, Infusion)